Anne S Raber
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Research Subjects
Research Interests
Anne S Raber has a total of 3 co-authors. Here are the top co-authors by number of shared publications:
- Ankit Mittal
Biopharmaceutics and Pharmaceutical Technology; Saarland University; Saarbruecken, Germany
1 shared publication - Claus-Michael Lehr
Helmholtz-Institute for Pharmaceutical Research Saarland (HIPS), Campus E8.1, 66123 Saarbrücken, Germany
1 shared publication - Steffi Hansen
Biopharmaceutics and Pharmaceutical Technology; Saarland University; Saarbruecken, Germany; Helmholtz Institute for Pharmaceutical Research Saarland (HIPS); Helmholtz Center for Infection Research; Saarbruecken, Germany
1 shared publication
Latest Publications
- Open Access
- 19 September 2013
- Published by Taylor & Francis in Human Vaccines & Immunotherapeutics
- Vol. 9 (9) , 1950-1955
Particle based vaccine formulations for transcutaneous immunization
Vaccine formulations on the basis of nano- (NP) or microparticles (MP) can solve issues with stabilization, controlled release, and poor immunogenicity of antigens. Likewise transcutaneous immunization (TCI) promises superior immunogenicity as well as the advantages of needle-free application compared with conventional intramuscular injections. Thus the combination of both strategies seems to be a very valuable approach. However, until now TCI using particle based vaccine formulations has made no impact on medical practice. One of the main difficulties is that NPs and MPs cannot penetrate the skin to an extent that would allow the application of the required dose of antigen. This is due to the formidable stratum corneum (SC) barrier, the limited amount of antigen in the formulation and often an insufficient immunogenicity. A multitude of strategies are currently under investigation to overcome these issues. We highlight selected methods presenting a spectrum of solutions ranging from transfollicular delivery, to devices disrupting the SC barrier and the combination of particle based vaccines with adjuvants discussing their advantages and shortcomings. Some of these are currently at an experimental state while others are already in clinical testing. All methods have been shown to be capable of transcutaneous antigen delivery.
- 19 September 2013
- Published by Taylor & Francis in Human Vaccines & Immunotherapeutics
- Vol. 9 (9) , 1950-1955
Open AccessParticle based vaccine formulations for transcutaneous immunization
Vaccine formulations on the basis of nano- (NP) or microparticles (MP) can solve issues with stabilization, controlled release, and poor immunogenicity of antigens. Likewise transcutaneous immunization (TCI) promises superior immunogenicity as well as the advantages of needle-free application compared with conventional intramuscular injections. Thus the combination of both strategies seems to be a very valuable approach. However, until now TCI using particle based vaccine formulations has made no impact on medical practice. One of the main difficulties is that NPs and MPs cannot penetrate the skin to an extent that would allow the application of the required dose of antigen. This is due to the formidable stratum corneum (SC) barrier, the limited amount of antigen in the formulation and often an insufficient immunogenicity. A multitude of strategies are currently under investigation to overcome these issues. We highlight selected methods presenting a spectrum of solutions ranging from transfollicular delivery, to devices disrupting the SC barrier and the combination of particle based vaccines with adjuvants discussing their advantages and shortcomings. Some of these are currently at an experimental state while others are already in clinical testing. All methods have been shown to be capable of transcutaneous antigen delivery.